How MRNA (Moderna) Makes Money in 2026: A Deep-Dive With Income Statement

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Understanding how a biotechnology company like Moderna (MRNA) makes money is essential for investors and anyone interested in the business of mRNA therapeutics. In this post, we break down Moderna's quarterly income statement (Q3 2025) using a Sankey chart to visualize the financial flows — what comes in, where it goes, and what's left as profit.

Quick Moderna Overview

Moderna operates as a biotechnology company focused on developing and commercializing mRNA-based medicines and vaccines. Revenue comes primarily from product sales, particularly its Spikevax COVID-19 vaccine, supplemented by grants, collaborations, and other sources. The company operates in a single segment centered on mRNA technology platform, with heavy emphasis on research and development for infectious diseases, oncology, and rare diseases.

Revenue Breakdown

• Total Revenue (Q3 2025): $1.016B (-45.2% YoY)
  • Product Sales Revenue: $973M (95.8% of total)
  • Other Revenue by Product: $20M (2.0% of total)
  • Grant Revenue: $14M (1.4% of total)
  • Collaboration Revenue: $7M (0.7% of total)
  • Other: $2M
  • Growth is powered by grant revenue doubling YoY, though overall revenue declined due to reduced demand for COVID-19 products amid market normalization.

Gross Profit and Margins

• Gross Profit: $809M (79.6% gross margin)
  • Cost of Revenue: $207M (-59.7% YoY)
  • Moderna maintains robust margins due to its scalable mRNA manufacturing platform and lower variable costs as COVID-19 vaccine volumes decline.
• Most costs come from manufacturing and supply chain for product sales, with significant YoY reductions reflecting optimized production.

Operating Income and Expenses

• Operating Income: -$260M (negative due to high R&D, no specific YoY or margin provided)
• Operating Expenses: $1.069B (-24.2% YoY)
  • R&D: $801M (-29.6% YoY, 78.8% of revenue) — focused on pipeline expansion including next-generation COVID-19 vaccines, RSV, flu, cancer therapies, and rare disease programs
  • SG&A: $268M (-4.6% YoY, 26.4% of revenue) — covers sales, marketing, and administrative functions supporting commercialization and partnerships
  • Moderna continues to prioritize innovation while maintaining efficiency through R&D cuts amid post-pandemic adjustments.

Net Income

• Pre-Tax Income: Not specified in data
• Income Tax: Not specified in data
• Net Income: $200M (0.0% YoY, 19.7% net margin)
• Moderna converts a significant portion of sales into profit due to high gross margins and other income offsetting operating losses.

Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.

Want to see what we'll uncover next - before everyone else does?

Find Hidden Gems First!

What Drives Moderna's Money Machine?

• Product Sales Revenue: 95.8%+ of revenue / Primarily from Spikevax COVID-19 vaccine sales, which face headwinds from lower demand but benefit from established manufacturing scale
• R&D Investment: $801M (78.8% of revenue) / Fuels a broad pipeline of 40+ programs across vaccines and therapeutics
• Pipeline Diversification: Heavy focus on oncology (e.g., mRNA-4157 personalized cancer vaccine) and respiratory vaccines (e.g., mRNA-1345 RSV)
• Future growth areas: Non-COVID programs like CMV vaccine and individualized neoantigen therapies, though not yet profitable

Visualizing Moderna's Financial Flows

The Sankey chart below visualizes how each dollar flows from gross revenue, through costs and expenses, down to net income. This helps investors spot where value is created, what areas weigh on profits, and how efficiently the company operates.

• Most revenue flows into gross profit, with operating expenses (especially R&D) taking the largest chunk.
• Even after large investments, 19.7% of revenue drops to the bottom line.

Key Takeaways

• Moderna's money comes overwhelmingly from product sales (Spikevax)
• High gross and net margins illustrate the power of Moderna's scalable mRNA platform
• Heavy investment in R&D, balanced by efficiency in operating costs
• Ongoing growth is driven by pipeline diversification beyond COVID-19

Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best overall value plays for 2026)

📌 50 Undervalued Dividend Stocks (For income-focused investors)

📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!

FAQ About Moderna's Income Statement

1. What is the main source of Moderna's revenue in 2025?

Moderna generates over 95.8% of its revenue from Product Sales Revenue. Grant revenue 1.4% and collaboration revenue 0.7% provide supplementary sources.

2. How profitable is Moderna in Q3 2025?

Moderna reported net income of $200M in Q3 2025, with a net margin of approximately 19.7%, reflecting strong profitability driven by high gross margins despite operating losses from R&D.

3. What are the largest expense categories for Moderna?

The biggest expenses on Moderna's income statement are operating expenses, particularly Research & Development (R&D) and Sales, General & Administrative (SG&A) costs. R&D investment reached $801M in Q3 2025, as Moderna prioritizes pipeline expansion in oncology and rare diseases.

4. Why does the core business operate at a loss?

The operating segment, despite generating $1.016B in revenue, posted an operating loss driven by $1.069B in expenses in Q3 2025. This is because Moderna aggressively invests in R&D for future mRNA therapies, believing these will drive long-term growth—even if unprofitable today.

5. How does Moderna's effective tax rate compare to previous years?

Moderna's effective tax rate in Q3 2025 was not specified in available data. This reflects data limitations, with net income achieved after other items.